Phibro Animal Health Corporation Class A (PAHC)

Phibro Animal Health Corp.'s stock has been positively impacted by strong financial performance and strategic developments. PAHC reported a substantial increase in net sales and net income for the six months ended December 31, 2025. Strong Q2 FY2026 results led to a stock surge and raised financial guidance for the full year ending June 30, 2026. The successful integration of the Zoetis medicated feed additive (MFA) portfolio has bolstered revenue. Insider selling by Chairman, President, and CEO Jack Bendheim was noted in late 2025 and early 2026.

Demand for Phibro Animal Health Corp.'s products and services exhibits seasonality. The company experiences seasonal demand strength driven by the healthy protein industry and seasonal disease patterns globally that influence the demand for animal health products.

Phibro Animal Health Corp. (PAHC) is a global animal health and mineral nutrition company that develops, manufactures, and markets products for food animals and is expanding into the companion animal sector. It operates through Animal Health, Mineral Nutrition, and Performance Products segments, with the Animal Health segment being the primary revenue driver. Phibro is the 7th largest animal health company globally, with revenues of US$978 million in 2023.

Phibro Animal Health Corp. has a significant international presence, selling its products in over 95 countries to around 4,000 customers. Its operations span the U.S., Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company maintains manufacturing bases in Brazil, Israel, the United States, and China.

Phibro Animal Health Corp.'s brand reputation has been positively influenced by its robust financial performance and strategic growth initiatives. The company's increase in net sales and net income, driven by the acquisition of Zoetis's medicated feed additive business, reflects effective market strategies. Phibro emphasizes its commitment to being a trusted partner for livestock producers, farmers, and veterinarians. There were no specific negative events found that significantly impacted Phibro Animal Health Corp.'s brand reputation in the past year.

The ownership structure of Phibro Animal Health Corp. includes both institutional and individual investors. The Bendheim family, through BFI Co., LLC, holds the majority of the company's voting power. Jack C. Bendheim, as Chairman and CEO, is the largest individual shareholder. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and State Street Corp.